| Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds, Non-Healing Leg Ulcers and Patients With Dystrophic Epidermolysis Bullosa. (NCT05378997) | Xinnate AB | 2022-04-07 |
| Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in People With Epidermolysis Bullosa. (NCT05288478) | University of Chile | 2022-04-06 |
| Improve Adherence to Weak or Strong Opioid Analgesics at the Time of Care in Children With Hereditary Epidermolysis Bullosa (NCT04853667) | Assistance Publique - Hôpitaux de Paris | 2021-04-29 |
| The State of Sexual Development in Children With Inherited Epidermolysis Bullosa (NCT05033574) | National Medical Research Center for Children's Health, Russian Federation | 2020-12-08 |
| Topical Gentamicin Nonsense Suppression Therapy of EB (NCT04644627) | Oslo University Hospital | 2020-12-01 |
| The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial (NCT04613102) | Elena Pope | 2020-08-01 |
| A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa (NCT04213703) | ProgenaBiome | 2020-03-02 |
| Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) (NCT04227106) | Abeona Therapeutics, Inc | 2020-01-10 |
| Pregabalin Treatment for RDEB Pain and Itch (NCT03928093) | The Hospital for Sick Children | 2019-08-07 |
| A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa (NCT03836001) | Stanford University | 2019-04-18 |
| Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex (NCT03389308) | Castle Creek Pharmaceuticals, LLC | 2017-12-01 |
| Computational Drug Repurposing for All EBS Cases (NCT03269474) | Joyce Teng | 2017-11-28 |
| Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa (NCT03158662) | Amicus Therapeutics | 2017-04-02 |
| Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa (NCT03068780) | Amryt Research Limited | 2017-03-29 |
| Evaluation of the Efficacy of ROPIVACAINE in Children and Young Adults With Hereditary Epidermolysis Bullosa (NCT03730584) | Assistance Publique - Hôpitaux de Paris | 2017-02-27 |
| Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa (NCT04217538) | Centre Hospitalier Universitaire de Nice | 2017-01-04 |
| Uses of Irradiated Human Amniotic Membrane in the Treatment of Dystrophic Epidermolysis Bullosa Patients (NCT03942250) | Egyptian Atomic Energy Authority | 2017-01-01 |
| Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients (NCT02654483) | Jean Yuh Tang | 2016-08-31 |
| Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa (NCT02793960) | Shasa Hu | 2016-08-10 |
| Study of Cellutome System for Treatment of Individual Lesions in EB Pts (NCT02670837) | Masonic Cancer Center, University of Minnesota | 2016-08-04 |
| MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs (NCT02582775) | Masonic Cancer Center, University of Minnesota | 2016-03-01 |
| Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa (NCT02670330) | Scioderm, Inc. | 2015-06-09 |
| ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa (NCT02384460) | Scioderm, Inc. | 2015-03-11 |
| Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa (NCT02090283) | Scioderm, Inc. | 2014-03-26 |
| Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa (NCT02014376) | Scioderm, Inc. | 2014-01-06 |
| A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing (NCT01749306) | Shire Regenerative Medicine, Inc. | 2012-12-01 |
| A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa (NCT01619670) | University Hospital, Basel, Switzerland | 2012-06-01 |
| Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes (NCT01454687) | Stanford University | 2011-10-01 |
| Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin (NCT01340235) | Centre Hospitalier Universitaire de Nice | 2011-06-01 |
| Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa (NCT01263379) | Abeona Therapeutics, Inc | 2010-10-05 |
| Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs (NCT01033552) | Masonic Cancer Center, University of Minnesota | 2010-01-01 |
| Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB) (NCT00881556) | Columbia University | 2009-08-20 |
| Study of Alwextin® Cream in Treating Epidermolysis Bullosa (NCT00825565) | Northwestern University | 2009-02-01 |
| Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa (NCT00478244) | Masonic Cancer Center, University of Minnesota | 2007-04-01 |
| Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys Bullosa (NCT00987142) | Tigenix S.A.U. | 2006-12-01 |
| A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa (NCT00311766) | RegeneRx Biopharmaceuticals, Inc. | 2006-02-01 |
| Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa (NCT00014729) | University of North Carolina | 2000-10-01 |
| Study of the Nutritional, Metabolic, and Body Composition Profile in Children and Adolescents With Epidermolysis Bullosa (NCT00004791) | National Center for Research Resources (NCRR) | 1995-08-01 |
| Establishment of the National Epidermolysis Bullosa Registry (NCT00004761) | National Center for Research Resources (NCRR) | 1986-09-01 |
| Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa (NCT00336154) | Rambam Health Care Campus | |